In the 2018/2019 business year, the company’s product portfolio consisted of 629 products

Egis Strengthens European Presence in the Biosimilar Area

Hungarian-based Egis Pharmaceuticals PLC signed an exclusive distribution agreement with Mundipharma network for a pegfilgrastim biosimilar. Pursuant to the agreement, Egis gains the exclusive distribution rights related to the medicine used to reduce a common side effect of cancer treatment called neutropenia and the related life-threatening infections. Thus, Egis gets the opportunity to launch this pegfilgrastim biosimilar product in four Eastern European countries.


A Journey to the Empire of Health: Focusing on Children

This March marks the official start of the Hungarian Nationwide Public Health Screening Program’s special campaign: the new initiative focuses on children’s health.


To Lead a Long and Healthy Life

Health means more than just the lack of illnesses.


Egis Attends Heart Day

Egis attended the event with a fork lift truck simulator that playfully presented the firm’s therapeutic areas.

WarningYour browser is out of date. Please, use an updated version! Chrome || Firefox